Alliance Pharma Regulatory News (APH)

16 May 2005 12:35

Alliance Pharma PLC16 May 2005 For Immediate Release 16 May 2005 ALLIANCE PHARMA PLC ("Alliance Pharma" or "the Company") Director's Share Dealing Alliance Pharma plc (AIM: APH), an emerging speciality pharmaceutical company,is pleased to announce that Michael Gatenby, Chairman of Alliance Pharma plc,purchased 50,000 shares at 14.45p, bringing his total in the company to 130,000shares which represents 0.088% of the total issued share capital. For further information: Alliance Pharma plc + 44 (0) 1249 466966John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000Mark Court/Lisa Baderoon/Rebecca Skye Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed emerging specialitypharmaceutical company based in Chippenham, Wiltshire, UK. The company has astrong track record of acquiring the rights to established niche brands andowns, or shares, the rights to 30 branded pharmaceutical products and continuesto explore opportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in the prevention of heart disease, inParkinson's disease, in nutrition, in nasal infections, in the treatment ofdermatological conditions and in childbirth. Alliance Pharma's sales are mainlyprescription driven. Its products are distributed to hospitals directly and topharmaceutical wholesalers which service both hospital and retail pharmacieswith their prescription requirements. Alliance Pharma is also developing new productsfor sleep disorders and the induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange